Neboglamine (INN ) (developmental code names CR-2249, XY-2401), formerly known as nebostinel, is a positive allosteric modulator of the glycine site of the NMDA receptor which is under investigation for Rottapharm for the treatment of schizophrenia and cocaine dependence.[1][2][3][4][5][6] It shows cognition- and memory-enhancing effects in animal models.[7][8][9] As of June 2015, it is in phase II clinical trials for both schizophrenia and cocaine abuse.[10]
Clinical data | |
---|---|
Other names | Nebostinel; N-(4,4-Dimethylcyclohexyl)-L-α-glutamine |
ATC code |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.162.081 |
Chemical and physical data | |
Formula | C13H24N2O3 |
Molar mass | 256.346 g·mol−1 |
3D model (JSmol) |
|
| |
|